TOP TEN perturbations for 39833_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39833_at
Selected probe(set): 214246_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39833_at (214246_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample
Relative Expression (log2-ratio):-2.3844862Number of Samples:8 / 8
| Experimental | PMA; ionomycine study 2 |
| CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:--- | |
| Control | unstimulated CD4 memory T-cell sample |
| Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects. |
tumor supernatant activation study 3 / untreated memory CD4 T-cell sample
Relative Expression (log2-ratio):-2.3614607Number of Samples:4 / 3
| Experimental | tumor supernatant activation study 3 |
| Memory (CD45RA-) CD4+ T cells isolated from peripheral blood of female healthy donors were incubated for 24 hours in 1:1 mix of tumor supernatant from primary invasive breast ductal carcinoma and X-VIVO 20 medium supplemented with antiCD3/CD28 beads, before harvest for RNA isolation. The tumor supernatant was prepared as followed: fresh surgical specimen was dissociated in X-VIVO 20 medium by GentleMACS dissociator and the resulting suspension was clarified by centrifugation for 15min at 13'000 g. ATC code:--- | |
| Control | untreated memory CD4 T-cell sample |
| Memory (CD45RA-) CD4+ T-cells were isolated from peripheral blood of healthy female donors and incubated in X-VIVO 20 medium for 24 hours, before harvest for RNA isolation. |
Alzheimer's disease study 7 / normal pyramidal neuron (hippocampus)
Relative Expression (log2-ratio):2.3187428Number of Samples:10 / 12
| Experimental | Alzheimer's disease study 7 |
| Pyramidal neurons collected from the CA1 region of the hippocampus of clinically and neuropathologically classified late-onset Alzheimer´s disease afflicted individuals. Subjects in this group had a Braak stage of V or VI with a CERAD score of moderate or frequent. | |
| Control | normal pyramidal neuron (hippocampus) |
| Pyramidal neurons collected from the CA1 region of the hippocampus of clinically classified as neurologically normal individuals. Subjects in this group had a Braak stage ranging from I to II with a infrequent Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuritic plaque density. |
T-helper activation study 1 (160min) / unstimulated helper T-cell sample
Relative Expression (log2-ratio):-2.071888Number of Samples:2 / 2
| Experimental | T-helper activation study 1 (160min) |
| Alloantigen specific helper T-cells were stimulated for 160min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors. | |
| Control | unstimulated helper T-cell sample |
| Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors. |
glioma study 17 (small cell glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):2.0159807Number of Samples:2 / 3
| Experimental | glioma study 17 (small cell glioblastoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade small cell glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 56 ± 3 years old males. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
T-helper activation study 1 (240min) / unstimulated helper T-cell sample
Relative Expression (log2-ratio):-1.9573975Number of Samples:2 / 2
| Experimental | T-helper activation study 1 (240min) |
| Alloantigen specific helper T-cells were stimulated for 240min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors. | |
| Control | unstimulated helper T-cell sample |
| Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors. |
Langerhans cell histiocytosis study 2 (multisystem) / normal epidermal Langerhans cell sample
Relative Expression (log2-ratio):-1.9296789Number of Samples:2 / 10
| Experimental | Langerhans cell histiocytosis study 2 (multisystem) |
| Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal, multisystem (disseminated) disease. Both patients received chemotherapy. Sites of LCH lesions: subj.ID:1 (skin, lungs, multiple skull, mastoid, gingiva), subj.ID:13 (mandible, skull, vertebrae, recurrent orbit, liver, spleen, pituitary gland). | |
| Control | normal epidermal Langerhans cell sample |
| Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue. |
T-helper activation study 1 (140min) / unstimulated helper T-cell sample
Relative Expression (log2-ratio):-1.8978481Number of Samples:2 / 2
| Experimental | T-helper activation study 1 (140min) |
| Alloantigen specific helper T-cells were stimulated for 140min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors. | |
| Control | unstimulated helper T-cell sample |
| Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors. |
expO skin cancer study 1 (squamous cell carcinoma, NOS; metastatic) / expO skin cancer study 1 (malignant melanoma, NOS; metastatic)
Relative Expression (log2-ratio):1.8918009Number of Samples:2 / 9
| Experimental | expO skin cancer study 1 (squamous cell carcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary squamous cell carcinoma (NOS) of the skin. | |
| Control | expO skin cancer study 1 (malignant melanoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary malignant melanoma (NOS) of the skin. |
B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)
Relative Expression (log2-ratio):1.8794394Number of Samples:4 / 4
| Experimental | B-CLL study 11 (rolipram) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
| Control | rolipram study 4 (normal B-cell; 20uM) |
| MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |